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Introduction
The introduction of biological agents has provided a
new therapeutic approach to the treatment of juvenile
idiopathic arthritis (JIA).
Aim
To analyze the data from a eight year follow-up of JIA
patients treated with biological agents.
Methods
Patients with JIA who started a biological treatment
were enrolled in a prospective observational study. Clin-
ical and laboratory data were recorded at baseline and
every 3 months.
Results
24 patients, 54% female, mean age at disease onset 7 ± 4
years, mean disease duration 11±8 years. 25% had
systemic arthritis, 25% rheumatoid factor (RF) positive
polyarthritis, 17% RF negative polyarthritis, 12% enthesi-
tis-related arthritis, and the remaining 21% were equally
distributed across the other groups. All patients had been
previously treated with at least one DMARD. The indica-
tion for biological treatment was DMARD failure in 86%
of the cases and MTX toxicity in the remaining 14%.
Biological treatment was started at a mean age of 15 ±
7 years and maintained for a mean of three years
(2 months- 7 years). 20 patients received etanercept,
3 infliximab and 1 anakinra as first-line biological. All
patients experienced a significant reduction in all disease
activity parameters at 3 months with maximum
improvement at six months (reduction in active joint
count of 92%, joints with limited range of motion 81%,
VAS 35%, ESR of 61%, CRP 88% (p<0.05)). This
response was sustained up to 7 years of treatment in
75% of the patients. The remaining 25% switched to a
second biological due to loss of efficacy.
Conclusion
Biological treatment was an effective and safe therapeu-
t i co p t i o ni nt h i sc o h o r to fp a t i e n t sw i t hs e v e r eJ I A
refractory or intolerant to classic DMARDs.
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